RS57086B1 - Supstituisani 3-haloalilamin inhibitori ssao i njihova primena - Google Patents

Supstituisani 3-haloalilamin inhibitori ssao i njihova primena

Info

Publication number
RS57086B1
RS57086B1 RS20180464A RSP20180464A RS57086B1 RS 57086 B1 RS57086 B1 RS 57086B1 RS 20180464 A RS20180464 A RS 20180464A RS P20180464 A RSP20180464 A RS P20180464A RS 57086 B1 RS57086 B1 RS 57086B1
Authority
RS
Serbia
Prior art keywords
compound
disease
pharmaceutically acceptable
acceptable salt
ssao
Prior art date
Application number
RS20180464A
Other languages
English (en)
Serbian (sr)
Inventor
Mandar Deodhar
Alison Dorothy Findlay
Jonathan Stuart Foot
Wolfgang Jarolimek
Ian Alexander Mcdonald
Alan Robertson
Craig Ivan Turner
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of RS57086B1 publication Critical patent/RS57086B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
    • C07C321/24—Thiols, sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
    • C07C321/26—Thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/63—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RS20180464A 2012-05-02 2013-04-05 Supstituisani 3-haloalilamin inhibitori ssao i njihova primena RS57086B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261641814P 2012-05-02 2012-05-02
EP13784562.4A EP2844637B1 (en) 2012-05-02 2013-04-05 Substituted 3-haloallylamine inhibitors of ssao and uses thereof
PCT/AU2013/000356 WO2013163675A1 (en) 2012-05-02 2013-04-05 Substituted 3-haloallylamine inhibitors of ssao and uses thereof

Publications (1)

Publication Number Publication Date
RS57086B1 true RS57086B1 (sr) 2018-06-29

Family

ID=49514094

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20180464A RS57086B1 (sr) 2012-05-02 2013-04-05 Supstituisani 3-haloalilamin inhibitori ssao i njihova primena

Country Status (24)

Country Link
US (4) US9302986B2 (enExample)
EP (2) EP3438087A1 (enExample)
JP (3) JP6182595B2 (enExample)
KR (2) KR20200030126A (enExample)
CN (2) CN107266332B (enExample)
AU (2) AU2013255103B2 (enExample)
BR (1) BR112014027406B1 (enExample)
CA (2) CA3086105A1 (enExample)
CY (1) CY1120334T1 (enExample)
DK (1) DK2844637T5 (enExample)
ES (1) ES2668300T3 (enExample)
HR (1) HRP20180953T1 (enExample)
HU (1) HUE038437T2 (enExample)
LT (1) LT2844637T (enExample)
ME (1) ME03063B (enExample)
MX (2) MX360634B (enExample)
NO (1) NO2842608T3 (enExample)
PL (1) PL2844637T3 (enExample)
PT (1) PT2844637T (enExample)
RS (1) RS57086B1 (enExample)
SG (2) SG10201707020TA (enExample)
SI (1) SI2844637T1 (enExample)
TR (1) TR201807453T4 (enExample)
WO (1) WO2013163675A1 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201707020TA (en) * 2012-05-02 2017-10-30 Boehringer Ingelheim Int Substituted 3-haloallylamine inhibitors of ssao and uses thereof
GB201304526D0 (en) 2013-03-13 2013-04-24 Proximagen Ltd New compounds
WO2015189534A1 (en) 2014-06-12 2015-12-17 Proximagen Limited Vap-1 inhibitors for treating muscular dystrophy
JP2018076236A (ja) * 2015-06-05 2018-05-17 株式会社アールテック・ウエノ がんを処置するための医薬組成物
JP2019502672A (ja) 2015-12-07 2019-01-31 ベネボレンタイ ケンブリッジ リミティド 疼痛の治療のためのｖａｐ−１阻害剤
BR112018067442A8 (pt) * 2016-02-12 2024-01-09 Pharmaxis Ltd Composto, composição farmacêutica, método de inibir a atividade da amina oxidase, método de tratar uma condição e uso de um composto
WO2018027892A1 (en) * 2016-08-12 2018-02-15 Eli Lilly And Company Amino pyrimidine ssao inhibitors
MX2019004549A (es) 2016-10-19 2019-06-12 Boehringer Ingelheim Int Combinaciones que comprenden un inhibidor ssao/vap-1 y un inhibidor sglt2 y usos de los mismos.
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
CN108341752B (zh) * 2017-01-21 2022-12-23 广东东阳光药业有限公司 抑制ssao/vap-1的胺类化合物及其在医药上的应用
WO2018148856A1 (en) * 2017-02-14 2018-08-23 Eli Lilly And Company Diazaspirodecanyl-pyrimidine compounds useful as ssao inhibitors
DK3589606T3 (da) * 2017-03-01 2024-01-02 Boehringer Ingelheim Int Overgangsmetal-katalyseret protodecarboxylering af alfa-halo-akrylsyrederivater
AU2018226610A1 (en) * 2017-03-02 2019-09-05 Pharmaxis Ltd. Haloallylamine pyrazole derivative inhibitors of lysyl oxidases and uses thereof
WO2018196677A1 (zh) * 2017-04-28 2018-11-01 四川科伦博泰生物医药股份有限公司 氟代烯丙胺衍生物及其用途
CA3060536A1 (en) * 2017-05-31 2018-12-06 Boehringer Ingelheim International Gmbh Pharmaceutical composition and pharmaceutical dosage form comprising (e)-4-(2-(aminomethyl)-3-fluoroallyloxy)-n-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof
GB201709136D0 (en) * 2017-06-08 2017-07-26 Proximagen Ltd New therapeutic uses of enzyme inhibitors
KR102187608B1 (ko) 2017-06-20 2020-12-08 산동 단홍 파머수티컬 컴퍼니., 리미티드. Ssao 억제제
CN109251166B (zh) * 2017-07-13 2021-11-05 广东东阳光药业有限公司 抑制ssao/vap-1的胺类化合物及其在医药上的应用
CN110914234B (zh) * 2017-08-04 2023-06-23 广东东阳光药业有限公司 抑制ssao/vap-1的胺类化合物及其在医药上的应用
CN109810041B (zh) 2017-11-21 2023-08-15 药捷安康(南京)科技股份有限公司 卤代烯丙基胺类ssao/vap-1抑制剂及其应用
CN109988106B (zh) * 2017-12-29 2023-03-31 广东东阳光药业有限公司 抑制ssao/vap-1的胺类化合物及其在医药上的应用
CN109988109B (zh) 2017-12-29 2020-12-29 广东东阳光药业有限公司 抑制ssao/vap-1的胺类化合物及其用途
KR20190110740A (ko) 2018-03-21 2019-10-01 주식회사유한양행 신규의 아릴 또는 헤테로아릴 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
KR20190110736A (ko) 2018-03-21 2019-10-01 주식회사유한양행 신규의 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
KR20200138283A (ko) 2018-03-22 2020-12-09 바이킹 테라퓨틱스 인코포레이티드 결정질 형태, 및 결정질 형태의 화합물을 제조하는 방법
WO2020006177A1 (en) * 2018-06-29 2020-01-02 Blade Therapeutics, Inc. Vascular adhesion protein-1 (vap-1) modulators and therapeutic uses thereof
KR20200004036A (ko) 2018-07-03 2020-01-13 주식회사유한양행 (e)-(2-(클로로메틸)-3-플루오로알릴)카바메이트 유도체의 제조방법
US12178791B2 (en) * 2018-08-03 2024-12-31 Syntara Limited Haloallylamine sulfone derivative inhibitors of lysyl oxidases and uses thereof
CN110938059A (zh) 2018-09-25 2020-03-31 上海轶诺药业有限公司 胺基脲敏感性胺氧化酶抑制剂制备及其应用
WO2020063854A1 (zh) * 2018-09-27 2020-04-02 南京明德新药研发有限公司 作为vap-1抑制剂的喹啉类衍生物
US11787791B2 (en) 2018-09-28 2023-10-17 Acucela Inc. Inhibitors of VAP-1
JP7615025B2 (ja) * 2018-09-28 2025-01-16 アキュセラ インコーポレイテッド Ｖａｐ－１の阻害剤
AU2019365213A1 (en) * 2018-10-24 2021-06-03 Metacrine, Inc. SSAO inhibitors and uses thereof
WO2020089025A1 (en) 2018-10-29 2020-05-07 Boehringer Ingelheim International Gmbh Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
WO2020089026A1 (en) * 2018-10-29 2020-05-07 Boehringer Ingelheim International Gmbh Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
EP3890747A4 (en) 2018-12-05 2022-08-03 Viking Therapeutics, Inc. COMPOSITIONS FOR THE TREATMENT OF FIBROSIS AND INFLAMMATION
JP2022510690A (ja) * 2018-12-05 2022-01-27 バイキング・セラピューティクス・インコーポレイテッド 肝障害の処置のための組成物及び方法
TW202039486A (zh) 2018-12-14 2020-11-01 南韓商柳韓洋行股份有限公司 三唑并吡啶-3-酮化物或其鹽及包含彼之醫藥組合物
TWI835945B (zh) 2018-12-14 2024-03-21 南韓商柳韓洋行股份有限公司 3,3-二氟烯丙胺化物或其鹽及包含彼的醫藥組合物
WO2020125776A1 (zh) 2018-12-20 2020-06-25 山东丹红制药有限公司 式(iv)化合物的工艺路线、晶型及其制备方法
MX2021006724A (es) 2019-01-11 2021-11-04 Transthera Sciences Nanjing Inc Compuestos de halo-alilamina y uso de los mismos.
WO2020233583A1 (zh) * 2019-05-20 2020-11-26 广东东阳光药业有限公司 抑制ssao/vap-1的异喹啉酮类化合物及其用途
BR112022000782A2 (pt) * 2019-07-25 2022-03-15 Pharmaxis Ltd Composto, composição farmacêutica, processo para preparar um composto, composto intermediário, e, uso de um composto, ou de um sal farmaceuticamente aceitável ou solvato do mesmo, ou de uma composição farmacêutica
BR112022007974A2 (pt) 2019-10-29 2022-07-12 Eccogene Shanghai Co Ltd Inibidores de ssao e uso dos mesmos
WO2021102774A1 (zh) * 2019-11-28 2021-06-03 广东东阳光药业有限公司 一种作为ssao/vap-1抑制剂的胺类衍生物及其用途
JP2023529255A (ja) * 2020-03-25 2023-07-10 ターンズ・インコーポレイテッド 呼吸障害の治療
CN111654920B (zh) * 2020-06-02 2022-03-11 重庆邮电大学 一种分布式能效子载波功率分配方法
WO2021258159A1 (en) * 2020-06-26 2021-12-30 Pharmaxis Ltd. Haloallylamine dual amine oxidase inhibitors
KR20230058112A (ko) 2020-08-25 2023-05-02 일라이 릴리 앤드 캄파니 Ssao 억제제의 다형체
CN114621189B (zh) * 2020-12-14 2024-01-02 上海拓界生物医药科技有限公司 一种内酰胺类衍生物及其用途
CN114621190B (zh) * 2020-12-14 2023-12-05 上海拓界生物医药科技有限公司 一种烯丙基胺类衍生物及其用途
CN114621243B (zh) * 2020-12-14 2024-03-01 上海拓界生物医药科技有限公司 一种磺酰胺类衍生物及其用途
CN119968356A (zh) * 2022-08-29 2025-05-09 辛塔拉有限公司 新型赖氨酰氧化酶选择性抑制剂
CN121175053A (zh) 2023-05-24 2025-12-19 勃林格殷格翰动物保健有限公司 包含一或多种sglt-2抑制剂及替米沙坦的非人类哺乳动物中肾脏疾病和/或高血压的组合治疗和/或预防
WO2025107036A1 (en) * 2023-11-23 2025-05-30 Syntara Limited Dual inhibitors of amine oxidases and peroxidases, and uses thereof

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
USRE28819E (en) 1972-12-08 1976-05-18 Syntex (U.S.A.) Inc. Dialkylated glycol compositions and medicament preparations containing same
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4358603A (en) 1981-04-16 1982-11-09 Syntex (U.S.A.) Inc. Acetal stabilized prostaglandin compositions
US4454158A (en) 1981-06-01 1984-06-12 Merrell Toraude Et Compagnie Allyl amine MAO inhibitors
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
ZA855101B (en) * 1984-07-13 1986-05-28 Merrell Dow Pharma Fluoroallylaine derivatives
US4699928A (en) 1984-07-13 1987-10-13 Merrell Dow Pharmaceuticals Inc. Fluoroallylamine derivatives
US4650907A (en) 1985-12-05 1987-03-17 Merrell Dow Pharmaceuticals Inc. Nonaromatic fluoroallylamine MAO inhibitors
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US6024975A (en) 1992-04-08 2000-02-15 Americare International Diagnostics, Inc. Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US5983134A (en) 1995-04-23 1999-11-09 Electromagnetic Bracing Systems Inc. Electrophoretic cuff apparatus drug delivery system
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US6167301A (en) 1995-08-29 2000-12-26 Flower; Ronald J. Iontophoretic drug delivery device having high-efficiency DC-to-DC energy conversion circuit
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US5985317A (en) 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
NZ334914A (en) 1996-10-01 2000-09-29 Stanford Res Inst Int Taste-masked microcapsule compositions and methods of manufacture using a phase seperation-coacervation technique
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
WO1999021537A1 (fr) 1997-10-28 1999-05-06 Bando Chemical Industries, Ltd. Feuille de timbre cutane et procede de production d'une feuille de base pour timbre
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
US6256533B1 (en) 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
WO2004018997A2 (en) 2002-08-20 2004-03-04 Neurogenetics, Inc. Methods and compositions for modulating amyloid beta
CN1921841A (zh) * 2004-02-25 2007-02-28 拉卓拉药物公司 用于治疗疾病的胺和酰胺类化合物
WO2005082343A2 (en) 2004-02-25 2005-09-09 La Jolla Pharmaceutical Company Amines and amides for the treatment of diseases
US9161922B2 (en) 2005-07-01 2015-10-20 Case Western Reserve University Amine oxidase inhibitors
US20070293548A1 (en) * 2006-03-31 2007-12-20 Wang Eric Y Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases
KR20090035707A (ko) 2006-07-19 2009-04-10 더 오하이오 스테이트 유니버시티 리서치 파운데이션 선택적인 안드로겐 수용체 모듈레이터, 그 유사체와 유도체, 및 그의 용도
EP2213303A4 (en) 2007-10-19 2011-12-28 R Tech Ueno Ltd PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CATARACT
WO2009061830A1 (en) 2007-11-06 2009-05-14 Massachusetts Eye & Ear Infirmary Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap-1) inhibitor
SG186008A1 (en) * 2007-11-21 2012-12-28 Pharmaxis Ltd Haloallylamine inhibitors of ssao/vap-1 and uses therefor
UA112154C2 (uk) 2009-09-08 2016-08-10 Біоті Терапіс Корп. Застосування повністю людського анти-vap-1-антитіла для лікування фіброзних станів
GB201004311D0 (en) 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
SG10201707020TA (en) * 2012-05-02 2017-10-30 Boehringer Ingelheim Int Substituted 3-haloallylamine inhibitors of ssao and uses thereof

Also Published As

Publication number Publication date
MX360634B (es) 2018-11-12
JP6182595B2 (ja) 2017-08-16
US20180086698A1 (en) 2018-03-29
CN104520268B (zh) 2017-05-24
HK1203477A1 (en) 2015-10-30
JP2015521167A (ja) 2015-07-27
HK1245237A1 (zh) 2018-08-24
LT2844637T (lt) 2018-05-10
SG11201406948PA (en) 2014-11-27
KR102089935B1 (ko) 2020-03-18
KR20200030126A (ko) 2020-03-19
US10160723B2 (en) 2018-12-25
EP3438087A1 (en) 2019-02-06
US9302986B2 (en) 2016-04-05
DK2844637T5 (en) 2018-08-13
EP2844637A4 (en) 2015-12-09
SG10201707020TA (en) 2017-10-30
JP2017132767A (ja) 2017-08-03
BR112014027406B1 (pt) 2020-09-24
US20160244406A1 (en) 2016-08-25
PT2844637T (pt) 2018-04-17
NO2842608T3 (enExample) 2018-07-21
CA3086105A1 (en) 2013-11-07
CN107266332A (zh) 2017-10-20
ES2668300T3 (es) 2018-05-17
DK2844637T3 (en) 2018-04-23
WO2013163675A1 (en) 2013-11-07
CA2871793A1 (en) 2013-11-07
CA2871793C (en) 2020-09-15
SI2844637T1 (en) 2018-07-31
JP2020019810A (ja) 2020-02-06
US9815782B2 (en) 2017-11-14
HUE038437T2 (hu) 2018-10-29
US20190071396A1 (en) 2019-03-07
PL2844637T3 (pl) 2018-09-28
BR112014027406A2 (pt) 2017-06-27
TR201807453T4 (tr) 2018-06-21
CN107266332B (zh) 2020-07-24
EP2844637B1 (en) 2018-03-28
CN104520268A (zh) 2015-04-15
ME03063B (me) 2019-01-20
JP6602802B2 (ja) 2019-11-06
AU2013255103A1 (en) 2014-11-06
EP2844637A1 (en) 2015-03-11
CY1120334T1 (el) 2019-07-10
MX2014013294A (es) 2015-05-08
MX377635B (es) 2025-03-11
AU2013203655B2 (en) 2017-02-02
HRP20180953T1 (hr) 2018-07-27
AU2013255103B2 (en) 2016-09-29
AU2013203655A1 (en) 2013-11-21
KR20150014926A (ko) 2015-02-09
US20150158813A1 (en) 2015-06-11

Similar Documents

Publication Publication Date Title
US10160723B2 (en) Substituted 3-haloallylamine inhibitors of SSAO and uses thereof
EP2046775B1 (fr) Derives de n- (amino-heteroaryl) - 1h-indole-2 -carboxamides comme antagonistes des recepteurs de type trpv1 ou vr1
KR20180082558A (ko) 에스테르 acc 억제제 및 그의 용도
KR20180082556A (ko) 피라졸 acc 억제제 및 그의 용도
JP2014533281A (ja) Ａｃｃ阻害剤およびその使用
WO2009085226A2 (en) Inhibitors of cdc2-like kinases (clks) and methods of use thereof
CN116157387A (zh) 异喹啉化合物及其在治疗AhR失衡中的用途
HK1203477B (en) Substituted 3-haloallylamine inhibitors of ssao and uses thereof
HK1245237B (zh) Ssao的取代的3-卤代烯丙基胺抑制剂及其用途
CN111138422B (zh) 一种用于防治红斑狼疮的药物及其制备方法
WO2025199211A1 (en) Imidazopyridines and imidazopyrimidines, and methods of using same
CN118684668A (zh) 螺环类化合物及其药物组合物、制备方法和用途